Literature DB >> 28943118

Roles of Clinical Research Networks in Pediatric Drug Development.

Mark A Turner1, Sabah Attar2, Saskia N de Wildt3, Gilles Vassal4, Laura Mangiarini5, Carlo Giaquinto6.   

Abstract

The evaluation of drugs that are used in children has been neglected historically but is now well established as an essential part of clinical drug development. The increase in pediatric activity among industry, and other sectors, has highlighted the importance of joint working. All participants in pediatric drug development need to be aware of the "big picture." An increasingly important part of this big picture in pediatrics, as in other populations, is the design and conduct of clinical trials in networks. This narrative review provides an overview of the roles of clinical research networks in pediatric drug development. Networks take many forms as specialty networks and geographic networks but work toward common principles, including sharing resources between trials, and using experience with trial conduct to improve trial design. Networks develop standardized processes for trial conduct (including performance management) that increase the speed and predictability of trial conduct while reducing burdens on sites, sponsors, and intermediaries. Networks can provide validated, real-world information about natural history, participant distribution, and standards of care to inform planning of development programs, including extrapolation and clinical trial simulation. Networks can work across geographic and jurisdictional barriers to promote global interoperability of drug development. Networks support participant centrality. Networks offer an opportunity to develop relationships with investigators, sites, and methodological experts that span pre-competitive foundations for drug development and specific products. Sustainable networks benefit all stakeholders by providing a multifunctional platform that promotes the quality and timeliness of clinical drug development.
Copyright © 2017 Elsevier HS Journals, Inc. All rights reserved.

Entities:  

Keywords:  academia; industry; integrated drug development; pediatrics; research networks

Mesh:

Year:  2017        PMID: 28943118     DOI: 10.1016/j.clinthera.2017.09.001

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  9 in total

Review 1.  Developmental Pharmacodynamics and Modeling in Pediatric Drug Development.

Authors:  Laurie S Conklin; Eric P Hoffman; John van den Anker
Journal:  J Clin Pharmacol       Date:  2019-09       Impact factor: 3.126

2.  How is the Pharmaceutical Industry Structured to Optimize Pediatric Drug Development? Existing Pediatric Structure Models and Proposed Recommendations for Structural Enhancement.

Authors:  Thomas Severin; Solange Corriol-Rohou; Christina Bucci-Rechtweg; Kristina An Haack; Sabine Fuerst-Recktenwald; Pirkko Lepola; Ensio Norjavaara; Martine Dehlinger-Kremer; Sebastian Haertter; S Y Amy Cheung
Journal:  Ther Innov Regul Sci       Date:  2020-02-06       Impact factor: 1.778

3.  Study factors associated with the incompletion of clinical trials that include pediatric patients: a retrospective analysis of the European Clinical Trials Database and a lesson from the European region.

Authors:  Nanae Tanemura; Tsuyoshi Sasaki; Junko Sato; Hisashi Urushihara
Journal:  Trials       Date:  2021-03-12       Impact factor: 2.279

4.  Analysis of Paediatric Clinical Trial Characteristics and Activity Over 23 Years-Impact of the European Paediatric Regulation on a Single French Clinical Research Center.

Authors:  Johanna Arnadottir; François Luc; Florentia Kaguelidou; Evelyne Jacqz-Aigrain
Journal:  Front Pediatr       Date:  2022-04-26       Impact factor: 3.418

5.  Informed consent and assent guide for paediatric clinical trials in Europe.

Authors:  Pirkko Lepola; Maxine Kindred; Viviana Giannuzzi; Heidi Glosli; Martine Dehlinger-Kremer; Harris Dalrymple; David Neubauer; Geraldine B Boylan; Jean Conway; Jo Dewhurst; Diane Hoffman
Journal:  Arch Dis Child       Date:  2021-12-01       Impact factor: 4.920

Review 6.  Pharmacogenomic testing in paediatrics: Clinical implementation strategies.

Authors:  Charlotte I S Barker; Gabriella Groeneweg; Anke H Maitland-van der Zee; Michael J Rieder; Daniel B Hawcutt; Tim J Hubbard; Jesse J Swen; Bruce C Carleton
Journal:  Br J Clin Pharmacol       Date:  2022-02-07       Impact factor: 3.716

Review 7.  Pediatric Rheumatology Collaborative Study Group - over four decades of pivotal clinical drug research in pediatric rheumatology.

Authors:  Hermine I Brunner; Lisa G Rider; Daniel J Kingsbury; Dominic Co; Rayfel Schneider; Ellen Goldmuntz; Karen B Onel; Edward H Giannini; Daniel J Lovell
Journal:  Pediatr Rheumatol Online J       Date:  2018-07-11       Impact factor: 3.054

Review 8.  The Challenges of Pediatric Drug Development.

Authors:  Klaus Rose
Journal:  Curr Ther Res Clin Exp       Date:  2019-01-26

9.  Capacity Building for a New Multicenter Network Within the ECHO IDeA States Pediatric Clinical Trials Network.

Authors:  Robert D Annett; Scott Bickel; John C Carlson; Kelly Cowan; Sara Cox; Mark J Fisher; J Dean Jarvis; Alberta S Kong; Jessica S Kosut; Kurtis R Kulbeth; Abbot Laptook; Pearl A McElfish; Mary M McNally; Lee M Pachter; Barbara A Pahud; Lee A Pyles; Jennifer Shaw; Kari Simonsen; Jessica Snowden; Christine B Turley; Andrew M Atz
Journal:  Front Pediatr       Date:  2021-07-14       Impact factor: 3.569

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.